NeuroBo Pharmaceuticals Files 8-K
Ticker: MTVA · Form: 8-K · Filed: Sep 30, 2024 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Neurobo Pharmaceuticals, INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | Sep 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, regulatory-filing
TL;DR
NeuroBo Pharma filed an 8-K on 9/30/24 for financial statements & exhibits.
AI Summary
NeuroBo Pharmaceuticals, Inc. filed an 8-K on September 30, 2024, reporting on its financial statements and exhibits. The company, formerly known as Gemphire Therapeutics Inc., is incorporated in Delaware and operates in the pharmaceutical preparations industry. Its principal executive offices are located in Cambridge, Massachusetts.
Why It Matters
This filing provides an update on NeuroBo Pharmaceuticals' regulatory and financial reporting, which is crucial for investors to stay informed about the company's status and any material events.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate operational or financial distress.
Key Numbers
- 001-37809 — SEC File Number (Identifies the company's filing with the SEC)
- 47-2389984 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- NeuroBo Pharmaceuticals, Inc. (company) — Registrant
- Gemphire Therapeutics Inc. (company) — Former company name
- September 30, 2024 (date) — Date of earliest event reported
- Cambridge, Massachusetts (location) — Principal executive offices
- 545 Concord Avenue, Suite 210 (address) — Principal executive offices address
FAQ
What specific financial statements are being reported in this 8-K filing?
The filing indicates that financial statements and exhibits are being reported, but the specific details of these statements are not provided in the provided text.
When was the company formerly known as Gemphire Therapeutics Inc.?
The date of the name change from Gemphire Therapeutics Inc. to NeuroBo Pharmaceuticals, Inc. was March 31, 2015.
What is the primary business of NeuroBo Pharmaceuticals, Inc.?
NeuroBo Pharmaceuticals, Inc. operates in the Pharmaceutical Preparations industry, with SIC code 2834.
Where are NeuroBo Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.
What is the purpose of filing a Form 8-K?
A Form 8-K is a report of unscheduled material events or corporate changes that are of interest to the public shareholders, such as the filing of financial statements and exhibits.
Filing Stats: 708 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2024-09-30 08:07:00
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share NRBO The Nasdaq Stock Mar
Filing Documents
- nrbo-20240930x8k.htm (8-K) — 46KB
- nrbo-20240930xex99d1.htm (EX-99.1) — 19KB
- nrbo-20240930x8k001.jpg (GRAPHIC) — 12KB
- nrbo-20240930xex99d1001.jpg (GRAPHIC) — 13KB
- 0001558370-24-013080.txt ( ) — 239KB
- nrbo-20240930.xsd (EX-101.SCH) — 3KB
- nrbo-20240930_lab.xml (EX-101.LAB) — 16KB
- nrbo-20240930_pre.xml (EX-101.PRE) — 10KB
- nrbo-20240930x8k_htm.xml (XML) — 5KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On September 30, 2024, NeuroBo Pharmaceuticals, Inc. (the "Company") issued a press release announcing positive top-line safety, tolerability, and dose-linear pharmacokinetics (PK) data from the single ascending dose (SAD) Part 1 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Report") and incorporated herein by reference. Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release is as inactive textual references only. Exhibit 99.1 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements. The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company's submission of this Report shall not be deemed an admissio
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release dated September 30, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROBO PHARMACEUTICALS, INC. Date: September 30, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer